Stephen Farr

Dr. Farr was most recently the Co-Founder, President and Chief Executive Officer of Zogenix, Inc. until May of 2022 upon the sale of Zogenix to UCB Pharma. Previously, Dr. Farr held positions of increasing responsibility at Aradigm Corporation from 1995 to 2006, serving most recently as Senior Vice President and Chief Scientific Officer. From 1986 to 1994, Dr. Farr was a tenured professor at the Welsh School of Pharmacy, Cardiff University, UK, concentrating in the areas of biopharmaceutics. Dr. Farr is a Director on the Board of SteadyMed (NASDAQ: STDY) and two private companies, Oscillari, LLC, and Flow Pharma, Inc. He is author/co-author of more than 180 scientific publications and patents and retains his academic interests as adjunct Professor in the Department of Pharmaceutics, School of Pharmacy, Virginia Commonwealth University, Richmond, VA.